Zonisamide in the treatment of bulimia nervosa: An open-label, pilot, prospective study

Authors

  • Anna I. Guerdjikova PhD, LISW,

    Corresponding author
    1. Lindner Center of HOPE, Mason, Ohio
    2. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
    • Correspondence to: Anna I. Guerdjikova, Lindner Center of HOPE and Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 4075 Old Western Row Road, Mason, OH 45040. E-mail: anna.guerdjikova@lindnercenter.org

    Search for more papers by this author
  • Thomas J. Blom MS,

    1. Lindner Center of HOPE, Mason, Ohio
    2. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author
  • Brian E. Martens MS,

    1. Lindner Center of HOPE, Mason, Ohio
    2. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author
  • Paul E. Keck Jr. MD,

    1. Lindner Center of HOPE, Mason, Ohio
    2. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author
  • Susan L. McElroy MD

    1. Lindner Center of HOPE, Mason, Ohio
    2. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author

ABSTRACT

Objective

To assess preliminarily the effectiveness of zonisamide in bulimia nervosa.

Method

This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency.

Results

Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged.

Discussion

In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2013; 46:747–750)

Ancillary